Therapeutic Asset Ratings

9,928 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Bendamustine Female Reproductive Organ Cancer	Mayo Clinic	P1	CC (43)
Bendamustine Hairy Cell Leukemia	City of Hope Medical Center	P1	CC (43)
Bendamustine Ovarian Carcinosarcoma	Mayo Clinic	P1	CC (43)
Bendamustine Prostate Cancer	Fred Hutchinson Cancer Center	P1	CC (43)
Bendamustine Malignant Pancreatic Neoplasm	Fred Hutchinson Cancer Center	P1	CC (43)
Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]- Epithelioid Hemangioendothelioma	Ikena Oncology	P1	CC (43)
Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]- Malignant Pleural Mesothelioma	Ikena Oncology	P1	CC (43)
Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]- NF2-Related Schwannomatosis	Ikena Oncology	P1	CC (43)
Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]- Mesothelioma	Ikena Oncology	P1	CC (43)
Berzosertib Bilateral Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Colorectal Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Lung Neuroendocrine Neoplasm	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Metastatic Malignant Neoplasm In The Brain	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Exocrine Pancreatic Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Colorectal Cancer	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Malignant Pancreatic Neoplasm	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Fallopian Tube Cancer	National Cancer Institute (NCI)	P1	CC (43)
Berzosertib Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Besufetamig T-Cell Non-Hodgkin Lymphoma	Ono Pharmaceutical Co., Ltd.	P1	CC (43)
Besufetamig Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Ono Pharmaceutical Co., Ltd.	P1	CC (43)
Bet Bromodomain Inhibitor Zen-3694 Breast Cancer	National Cancer Institute (NCI)	P1	CC (43)

Showing 1251 to 1275 of 9,928 assets

PreviousPage 51 of 398Next